A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.

CompletedOBSERVATIONAL
Enrollment

82

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

May 18, 2022

Study Completion Date

May 18, 2022

Conditions
Fabry Disease
Interventions
DRUG

Enzyme Replacement Therapy (ERT)

ERT infusion every other week

Trial Locations (9)

19104

Amicus Therapeutics, Inc., Philadelphia

Unknown

Instituto de Genética e Erros Inatos do Metabolismo (IGEIM), São Paulo

Keio University Hospital, Tokyo

Yokohama Municipal Citizen's Hospital, Yokohama

National Taiwan University, Taipei

Taipei Veterans General Hospital, Taipei

Gazi University Hospital, Ankara

Dokuz Eylul University Medical Faculty, Izmir

Ege University Hospital, Izmir

Sponsors
All Listed Sponsors
lead

Amicus Therapeutics

INDUSTRY

NCT04281537 - A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy. | Biotech Hunter | Biotech Hunter